IL326201A - 3-(4-ציקלו-פרופוקסיבנזיל)-1-(4,2-דיפלואורובנזיל)-1-(1-מתילפיפרידין-4-איל)אוריאה לשימוש בטיפול במחלות הקשורות לקולטן הסרוטונין 5-ht - Google Patents

3-(4-ציקלו-פרופוקסיבנזיל)-1-(4,2-דיפלואורובנזיל)-1-(1-מתילפיפרידין-4-איל)אוריאה לשימוש בטיפול במחלות הקשורות לקולטן הסרוטונין 5-ht

Info

Publication number
IL326201A
IL326201A IL326201A IL32620126A IL326201A IL 326201 A IL326201 A IL 326201A IL 326201 A IL326201 A IL 326201A IL 32620126 A IL32620126 A IL 32620126A IL 326201 A IL326201 A IL 326201A
Authority
IL
Israel
Prior art keywords
propoxybenzyl
difluorobenzyl
methylpiperidin
serotonin
cyclo
Prior art date
Application number
IL326201A
Other languages
English (en)
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of IL326201A publication Critical patent/IL326201A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326201A 2023-08-02 2024-08-01 3-(4-ציקלו-פרופוקסיבנזיל)-1-(4,2-דיפלואורובנזיל)-1-(1-מתילפיפרידין-4-איל)אוריאה לשימוש בטיפול במחלות הקשורות לקולטן הסרוטונין 5-ht IL326201A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363530291P 2023-08-02 2023-08-02
US202463554437P 2024-02-16 2024-02-16
PCT/US2024/040491 WO2025029990A1 (en) 2023-08-02 2024-08-01 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht

Publications (1)

Publication Number Publication Date
IL326201A true IL326201A (he) 2026-03-01

Family

ID=92543465

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326201A IL326201A (he) 2023-08-02 2024-08-01 3-(4-ציקלו-פרופוקסיבנזיל)-1-(4,2-דיפלואורובנזיל)-1-(1-מתילפיפרידין-4-איל)אוריאה לשימוש בטיפול במחלות הקשורות לקולטן הסרוטונין 5-ht

Country Status (5)

Country Link
KR (1) KR20260048603A (he)
AU (1) AU2024317004A1 (he)
IL (1) IL326201A (he)
MX (1) MX2026001167A (he)
WO (1) WO2025029990A1 (he)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI703130B (zh) * 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
MX2020001757A (es) 2017-08-21 2020-09-07 Acadia Pharm Inc Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.

Also Published As

Publication number Publication date
AU2024317004A1 (en) 2026-02-12
MX2026001167A (es) 2026-03-02
WO2025029990A1 (en) 2025-02-06
KR20260048603A (ko) 2026-04-10

Similar Documents

Publication Publication Date Title
WO2021203103A3 (en) Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
PH12012500809A1 (en) Methods and compositions for treating cancer
SG11202011872QA (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
ATE453642T1 (de) Substituierte phenylaminopyrimidine
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
WO2018060463A3 (en) Treatment of prostate cancer
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
MX2024008100A (es) Lactamas funcionalizadas novedosas como moduladores del receptor 7 de 5-hidroxitriptamina y su metodo de uso.
MX2020010879A (es) Carboxamidas biciclicas y metodos de uso de las mismas.
MY192494A (en) Vaginal composition and use thereof
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2019103658A3 (ru) Производные 1,4-бензодиазепин-2-она и их применение
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
NZ811397A (en) Liquid tasimelteon formulations and methods of use thereof
CA3264923A1 (en) COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE
CL2009000491A1 (es) Compuestos derivados de 3-(4-(2-oxoindol)-piperidin)-pirrolidinas y 3-(4-benzo[b]imidazol)-piperidin)-pirrolidinas sustituidas proceso de preparacion; composicion farmaceutica; compuestos intermediarios; utiles en el tratamiento de la terapia del dolor, de enfermedades tales como alzheimer, ansiedad, depresion y glaucoma.
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
MXPA05003264A (es) Pirroles 3,4-disustituidos y su uso en el tratamiento de enfermedades inflamatorias.
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole